Skip to main content

Table 1 Chemotherapy regimen and positive cases detected

From: High incidence of microsatellite instability and loss of heterozygosity in three loci in breast cancer patients receiving chemotherapy: a prospective study

Chemotherapy regimen

No. of patients

No. of MSI-H

No. of MSI-L-

Recurrence /2ndCA

High conc. FEC a

68

19

37

14

5-Floururacil 500 mg/m2

    

Epirubicin 90–100 mg/m2

    

Cyclophosphamide 600 mg/m2

    

Low conc. FEC a

31

4

18

2

5-Floururacil 300–400 mg/m2

    

Epirubicin 50–75 mg/m2

    

Cyclophosphamide 400 mg/m2

    

AC b

13

0

6

0

Adriamycin (Doxorubicin) 60 mg/m2

    

Cyclophosphamide 600 mg/m2

    

TC c

3

0

2

0

Taxotere (Docetaxel) 75 mg/m2

    

Cyclophosphamide 600 mg/m2

    

PT d

2

0

1

0

Carboplatin (Paraplatin) AUC 6 mg/ml/min

    

Taxotere 175 mg/m2

    

TA e

1

0

0

0

Taxotere 90 mg/m2

    

Avastin (Bevacizumab) 10 mg/kg

    

TH f

3

0

0

0

Taxotere 90 mg/m2

    

Herceptin (Trastuzumab) 4 mg/kg

    

LT g

1

0

0

0

Lapatinib (Tykerb) 1500 mg po

    

Taxotere 175 mg/m2

    

TE h

1

0

0

0

Epirubicin 75 mg/m2

    

Taxotere 200 mg/m2

    

Total

123

23

64

16

  1. Abbreviations: a = 5-Floururacil, Epirubicin and Cyclophosphomide, b = Adriamycin and Cyclophosphamide, c = Taxotere and Cyclophosphamide, d = Paraplatin and Taxotere, e = Taxotere and Avastin, f = Taxotere and Herceptin, g = Lapatinib and Taxotere, h = Epirubicin and Taxotere.